For the year ending 2025-12-31, SGMT had -$40,819K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -51,038 |
| Accretion of discount on marketable securities | 389 |
| Non-cash operating lease expense | 151 |
| Stock-based compensation expense | 6,449 |
| Write-off of deferred financing costs | 230 |
| Prepaid expenses and other current assets | 1,830 |
| Accounts payable, accrued expenses and other current liabilities | 929 |
| Operating lease liabilities | -152 |
| Net cash used in operating activities | -45,650 |
| Purchases of marketable securities | 106,864 |
| Sales and maturities of marketable securities | 111,420 |
| Net cash provided by (used in) investing activities | 4,556 |
| Proceeds from sale of series a common stock, net of issuance costs | 0 |
| Payment of financing costs | 0 |
| Proceeds from exercise of stock options | 275 |
| Net cash provided by financing activities | 275 |
| Net (decrease) increase in cash and cash equivalents | -40,819 |
| Cash and cash equivalents at beginning of period | 75,840 |
| Cash and cash equivalents at end of period | 35,021 |
Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT)